Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 3
Submit an article Journal homepage
73
Views
27
CrossRef citations to date
0
Altmetric
Research Article

Combined Fludarabine and Rituximab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia

David G. Savage New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
,
Neil S. Cohen Stamford Hospital, Stamford, CT, USA
,
Charles S. Hesdorffer New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
,
Daniel Heitjan New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
,
Martin W. Oster New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
,
Thomas J. Garrett New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
,
Michael Bar Stamford Hospital, Stamford, CT, USA
,
Salvatore del Prete Stamford Hospital, Stamford, CT, USA
,
Robert March New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
,
Mathew Lonberg New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
,
Susan Talbot New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
,
J. Gregory Mears New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
,
Michael Flamm New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
,
Robert N. Taub New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
&
Gwen Nichols New York Presbyterian Hospital, Columbia Campus, New York, NY 10032, USA
 show all
Pages 477-481 | Published online: 01 Jul 2009

  • Hiddeman, W., Rottmann, R., Wormann, B., Thiel, A., Essink, M., Ottensmeier, C., Freund, M, Buchner, T. and van de Loo, J. (1991) "Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase II study", Ann. Hematol. 63, 1-4.
  • Redman, I.R., Cabanillas, E, Velasquez, W.S., McLaughlin, P., Hagemeister, F.B., Swan, F, Jr., Rodriguez, M.A., Plunkett, W.K. and Rearing, M.J. (1991) "Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma", J. Clin. Oncol. 10, 790-794.
  • Hochster, H.S., Kim, K., Green, M.D., Mann, R.B., Neiman, R.S., Oken, M.M., Cassileth, P.A., Stott, P., Ritch, P. and O'Connell, M.J. (1992) "Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study", J. Clin. Oncol. 10, 28-32.
  • Solal-Céligny, P., Brice, P., Brousse, N., Gaspard, H., Bastion, Y, Haioun, C, Bosly, A., Tilly, H., Bordessoule, D., Sebban, C, Harousseau, J.L., Morel, P., Dupas, B., Plassart, F., Vasile, N., Fort, N. and Leporrier, M. (1996) "Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte", J. Clin. Oncol. 14, 514-519.
  • Johnson, S., Smith, A.G., Osby, E., Juliusson, G., Emmerich, B., WyId, P.J. and Hiddemann, W. (1996) "Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL", Lancet 347, 1432-1438.
  • Sorensen, J.M., Vena, D.A., Fallavollita, A., Chun, H.G. and Cheson, B.D. (1997) 'Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C protocol mechanism of the National Cancer Institute: five-year follow-up report", J. Clin. Oncol. 15, 458-465.
  • Leblond, V., Ben-Othman, T., Deconinck, E., Taksin, A.L., Harousseau, J.L., Delgado, M.A., Delmer, A., Maloisel, E., Mariette, X., Morel, P., Clauvel, J.P., Duboisset, P., Entezam, S., Hermine, O., Merlet, M., Yakoub-Agha, I., Guibon, O., Gaspard, H., and Fort, N. (1998) "Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: a report of 71 cases", J. Clin. Oncol. 16, 2060-2064.
  • Rearing, M.J., O'Brien, S., Lerner, S., Koller, C., Beran, M., Robertson, L.E., Freireich, E. J., Estey, E. and Rantarjian, H. (1998) "Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy", Blood 91, 1165-1171.
  • Foran, J.M., Rohatiner, A.Z.S., Coiffier, B., Barbui, T., Johnson, S.A., Hiddemann, W., Radford, J.A., Norton, A.J., Tollerfield, S.M., Wilson, M.P. and Lister, T.A. (1999) "Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma", J. Clin. Oncol. 17, 546-553.
  • Hagenbeek, A., Eghbali, H., Monfardini, S., Resegotti, E., Hoskin, J., de Wolf-Peeters, C., McLennan, K. and Teodorovic, I. (1998) "Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stages HI and IV low grade malignant non-Hodgkin's lymphoma. Preliminary results from a prospective, randomized phase III clinical trial in 381 patients", Blood 92, 315a (abstract 1294).
  • Klasa, R., Meyer, R., Shustik, C., Sawka, C., Smith, A., Grenier, J.F. and Beruhe, S. (1999) "Fludarabine versus CVP in previously treated patients with progressive low grade non-Hodgkin's lymphomas (Ig-NHL)", J. Clin. Oncol. 18, 9a (abstract 28).
  • Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M.J., Jaubert, J., Autrand, C., Divine, M., Dreyfus, B., Maloum, K., Travade, P., Dighiero, G., Binet, J.L. and Chastang, C. (2001) "Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. French Cooperative Group on Chronic Lymphocytic Leukemia", Blood 98, 2319-2325.
  • Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. and Schiffer, C.A. (2000) "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia", N. Engl. J. Med. 343, 1750-1757.
  • Dhodapkar, M.V, Jacobson, J.L., Gertz, M.A., Rivkin, S.E., Roodman, G.D., Tuscano, J.M., Shurafa, M., KyIe, R.A., Crowley, J.J. and Barlogie, B. (2001) "Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)", Blood 98, 41 -48.
  • Maloney, D.G., Liles, T.M., Czerwinski, O.K., Waldichuk, C., Rosenberg, I., Grillo-Lopez, A. and Levy, R. (1994) "Phase I clinical trial using escalating single-dose infusion of chimeric antiCD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma", Blood 84, 2457-2466.
  • Maloney, D.O., Grillo-Lopez, A.J., Bodkin, D.I., White, C.A., Liles, T.M., Royston, I., Yarns, C., Rosenberg, J. and Levy, R. (1997) "IDEC-C2B8: results of a phase I multiple dose trial in patients with relapsed non-Hodgkin's lymphoma", J. Clin. Oncol. IS, 3266-3274.
  • Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.M., Dallaire, B.K., Wey, K., Royston, I., Davis, T. and Levy, R. (1997) "IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma", Blood 90, 2188-2195.
  • McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, R, Jain, V, Ho, A.D., Lister, J., Wey, K., Shen, D. and Dallaire, B.K. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program", J. Clin. Oncol. 16, 2825-2833.
  • Byrd, J.C., White, C.A., Link, B., Lucas, M.S., Velasquez, W.S., Rosenberg, J. and Grillo-Lopez, A.J. (1999) "Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity", Ann. Oncol. 10, 1525-1527.
  • Davis, T.A., White, C.A., Grillo-Lopez, A.J., Velasquez, W.S., Link, B., Maloney, D.G., Dillman, R.O., Williams, M.E., Mohrbacher, A., Weaver, R., Dowden, S. and Levy, R. (1999) "Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab", J. Clin. Oncol. 17, 1851-1857.
  • Nguyen, D.T., Amess, J.A., Doughthy, H., Hendry, L. and Diamond, L.W. (1999) "IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients", Eur. J. Haematol. 62, 76-81.
  • Davis, T.A., Grillo-Lopez, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, B.K., Maloney, D.G., Weaver, R.L., Rosenberg, J. and Levy, R. (2000) "Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment", J. Clin. Oncol 18, 3135-3143.
  • Foran, J.M., Cunningham, D., Coiffier, B., Solal-Céligny, P., Reyes, E, Ghielmini, M., Johnson, P.W., Gisselbrecht, C., Bradburn, M., Matthews, J. and Lister, T.A. (2000) 'Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response", Ann. Oncol. 11(Suppl. 1), 117-121.
  • Foran, J.M., Gupta, R.K., Cunningham, D., Popescu, R.A., Goldstone, A.H., Sweetenham, J.W., Pettengell, R., Johnson, P.W., Bessell, E., Hancock, B., Summers, K., Hughes, J., Rohatiner, A.Z. and Lister, T.A. (2000) "A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response", Br. J. Haematol 109, 81-88.
  • Hainsworth, J.D., Bums, III, H.A., Morrissey, L.H., Litchy, S., Scullin, D.C., Jr., Bearden, J.D, 3rd., Richards, P. and Greco, EA. (2000) "Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma", Blood 95, 3052-3056.
  • Byrd, J.C., Murphy, T., Howard, R.S., Lucas, M.S., Goodrich, A., Park, K., Pearson, M., Waselenko, J.K., Ling, G., Grever, M.R., Grillo-Lopez, A.J., Rosenberg, J., Kunkel, L. and Flinn, I.W. (2001) "Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates significant clinical activity and acceptable toxicity", J. Clin. Oncol. 19, 2153-2164.
  • Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V, Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Stamatoullas, A., Milpied, N., Boue, F., Taillan, B., Lederlin, P., Najman, A., Thieblemont, C., Montestruc, P., Mathieu-Boue, A., Benzohra, A. and Solal-Céligny, P. (2001) "Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation", Blood 97, 101-106.
  • O'Brien, S., Freireich, E., Andreeff, M., Lerner, S. and Rearing, M. (1998) "Phase I/II study of Rituxan in chronic lymphocytic leukemia (CLL)", Blood 92, 105a (abstract).
  • Huhn, D., von Schilling, C., Wilhelm, M., Ho, A.D., Hallek, M., Kuse, R., Knauf, W., Riedel, U., Hinke, A., Stock, S., Serke, S., Peschel, C. and Emmerich, B. (2001) "Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. German Chronic Lymphocytic Leukemia Study Group", Blood 98, 1326-1331.
  • Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N. and Bonavida, B. (1997) "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs", Cancer Biother. Radiophar. 12, 177-186.
  • Alas, S., Bonavida, B. and Emmanouilides, C. (2000) "Potentiation of fludarabine cytotoxicity on non-Hodgkin lymphoma by pentoxifylline and rituximab", Anticancer Res. 5A, 2961 -2966.
  • Di Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J. and Introna, M. (2001) "Synergism between fludarbine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone", Br. J. Haematol. 114, 800-809.
  • Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.J., Connors, J.M., Lister, I.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. and Canellos, G.P. (1999) "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas", J. Clin. Oncol. 17, 1244-1250.
  • Cheson, B.D., Bennett, I.M., Grever, M, Kay, N., Rearing, M.J., O'Brien, S. and Rai, K.R. (1996) "National Cancer Institutesponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment", Blood 87, 4990-4999.
  • Byrd, J.C., Waselenko, J.K., Maneatis, T.J., Murphy, T., Ward, F.T., Monahan, B.P., Sipe, M.A., Donegan, S. and White, C.A. (1999) "Rituximab therapy in hematologie malignancy patients with circulating blood tumor cells: association with increased infusionrelated side effects and rapid blood tumor clearance", J. Clin. Oncol. 17,791-795.
  • Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V. and Engert, A. (1999) "Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)", Blood 94, 2217-2224.
  • Kunzmann, V, Ruediger, T., Hallek, M., Mueller-Hermelink, H.-K. and Wilhelm, M. (2001) "Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during antiCD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment", Blood 98, 1991-1992.
  • Czuczman, M.S., Fallon, A., Scarpace, A., Stewart, C., Bernstein, Z.P., McCarthy, P., Skipper, M., Brown, K., Miller, K., Wending, D., Rock, M.K., Benyunes, M., Grillo-Lopez, A. and Bernstein, S.H. (2000) "Phase II study of rituximab in combination with fludarabine in patients with low-grade or follicular B-cell lymphoma", Blood 96, 729a, (abstract 3154).
  • Byrd, J.C., Peterson, B., Park, K., Morrison, V., Vardiman, J.W., Iacobson, R.J., Rai, K. and Larson, R.A. (2001) "Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: preliminary results from CALGB 9712", J Clin. Oncol. 20, 280a, (abstract 1116).
  • Garica Manero, G., O'Brien, S., Cortes, J., Faderl, S., Giles, E, Albitar, M., Lerner, S., Kantarjian, H. and Rearing, M. (2001) "Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL)", Blood 98, 633a (abstract 2650).
  • Cabanillas, E, McLaughlin, P., Hagemeister, E, Rodriguez, M.A., Romaguera, I.E., Younes, A., Sarris, A.H., Pro, B., Dang, N., Samaniego, E and Lee, M.S. (2000) "Molecular responses with END + Rituxan chemoimmunotherapy for stage IV indolent follicular non-Hodgkin's lymphoma", Blood 96, 331a (abstract 1429).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.